This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies, potentially reducing treatment costs by tens to hundreds of thousands of dollars. Key objectives include establishing a BIKE production and validation system, creating bioluminescent tumor cell lines for more sensitive detection, and demonstrating the efficacy of the BIKE expression construct in a hepatocellular carcinoma mouse model. The project seeks to advance gene therapy approaches for cancer treatment by enabling efficient, redosable gene delivery and systemic secretion of the therapeutic.